RMD ASX Week ended 31 Jul 2026

Weekly Investor Report

ResMed Inc. · Healthcare · Medical Instruments & Supplies

Open interactive chart View report data
Latest close 29.79 AUD
8.6% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -6.5% below the Trend Line and sits at 22.0% of its 52-week range. The latest completed week returned 8.6%, after a -2.3% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 56/100.

Setup score 31 out of 100
Latest Close 29.79 AUD 31 Jul 2026
1W Return 8.6% latest completed week
4W Return -2.3% short-term follow-through
12W Return 4.5% quarterly tape
Trend Breadth 25.0% 13 of 52 weeks active
Volume Ratio 1.3x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
  • Latest weekly return ranks in the strongest part of its sector group.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 42.43% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 8.6% Latest completed week; four-week move -2.3%. Indicator stack 14/76 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.43% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 56/100 31 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -6.5% below the Trend Line and sits at 22.0% of its 52-week range. The latest completed week returned 8.6%, after a -2.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.3x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1712-week average 0.06

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.17Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.3% over four weeks, 4.5% over 12 weeks, and -30.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W8.6%
4W-2.3%
12W4.5%
26W-20.3%
52W-30.1%
Active trend streak0 weeks
Active weeks in one year13
Trend breadth25.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.63Latest activity-pressure read.
Pressure change179.6%Four-week change in activity pressure.
Leadership-17.32Latest relative-leadership reading.
RS change-6.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength20/100Blend of value, momentum, and quality. Underlying universe rank 81; rank 1 is best.
Value5/100Relative valuation strength. Underlying universe rank 96; rank 1 is best.
Quality100/100Profitability and accounting quality. Underlying universe rank 1; rank 1 is best.
Momentum7/100Medium-term price momentum. Underlying universe rank 94; rank 1 is best.
Growth90/100Revenue and earnings growth. Underlying universe rank 11; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework55/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
26.2x
Price divided by trailing earnings.
Price / sales
7.2x
Market value relative to trailing revenue.
EV / EBITDA
17.9x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
4.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
61.6%
Gross profit retained from each unit of revenue.
Operating margin
34.6%
Operating profit retained from revenue.
Free-cash-flow margin
31.4%
Free cash flow generated from revenue.
Return on invested capital
25.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
9.8%
Latest one-year revenue growth.
EPS growth
37.7%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
28.3%
Latest one-year free-cash-flow growth.
Piotroski F-score
8/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
1.3%
Cash dividends relative to market value.
Buyback yield
1.3%
Net share repurchases relative to market value.
Shareholder yield
2.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment56/100

Weighted news tone is neutral across 31 relevant articles.

13 positive · 17 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-33.8%Distance below the 52-week high.
13-week volatility4.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+8.6%Week of 31 Jul.
Worst week-9.7%Week of 13 Feb.
Latest week+8.6%Week of 31 Jul.

Shape of recent returns

Strong gains4
Modest gains6
Flat weeks0
Modest losses11
Sharp losses5
Recent vol4.5%13-week weekly-return volatility.
Base vol3.7%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew2.7% / -2.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape28/100

Trend, activity pressure, participation, and risk combine to a 28/100 tape read.

 Indicator analysis17/100

Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.

Activity pressure 0.17; No reversal markers Next-Week ExpectancyNegative 42.43%

Next-week expectancy is negative with a 42.43% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors34/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 5 SVQF55/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 119.0 of 262 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment56/100

Weighted news tone is neutral across 31 relevant articles.

ResMed Inc. stock rises Friday, outperforms market Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202629.79 AUD8.6%31.86 AUD33.00 AUD0.63-17.329.0MOff
24 Jul 202627.43 AUD-4.6%32.07 AUD33.00 AUD0.64-22.698.4MOff
17 Jul 202628.75 AUD-4.3%32.36 AUD33.03 AUD0.46-19.809.6MOff
10 Jul 202630.03 AUD-1.5%32.62 AUD33.05 AUD-0.13-16.818.1MOff
3 Jul 202630.50 AUD5.4%32.88 AUD33.06 AUD-0.79-16.329.4MOff
26 Jun 202628.94 AUD8.5%33.15 AUD33.07 AUD-1.35-20.282.6MOff
19 Jun 202626.68 AUD-3.8%33.50 AUD33.09 AUD-1.72-27.462.5MOff
12 Jun 202627.72 AUD0.3%33.86 AUD33.12 AUD-1.59-24.962.5MOff
5 Jun 202627.64 AUD-3.9%34.21 AUD33.14 AUD-1.53-24.0816.5MOff
29 May 202628.75 AUD-2.1%34.56 AUD33.17 AUD-1.53-22.441.7MOff
22 May 202629.37 AUD3.7%34.91 AUD33.19 AUD-1.42-20.516.8MOff
15 May 202628.33 AUD-0.6%35.29 AUD33.21 AUD-1.52-23.496.2MOff
8 May 202628.50 AUD-0.6%35.71 AUD33.24 AUD-1.48-24.509.0MOff
1 May 202628.67 AUD-7.0%36.16 AUD33.28 AUD-1.49-24.388.1MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.